Cisplatin Ebewe

Cisplatin Ebewe



EBEWE Pharma




Mega Lifesciences
Concise Prescribing Info
Monotherapy or as part of existing chemotherapy for advanced or metastatic tumours eg, testicular carcinoma (palliative & curative polychemotherapy), ovary carcinoma (stages III & IV) & head & neck squamous cell epithelioma (palliative therapy). Small cell lung carcinoma. Advanced non-small cell lung carcinoma.
Dosage/Direction for Use
Adult & childn Monotherapy 50-120 mg/m2 as single IV infusion over 6-8 hr every 3-4 wk or 15-20 mg/m2/day as IV infusion over 6-8 hr for 5 days every 3-4 wk. Combination chemotherapy Reduce dose to 20 mg/m2 or more once every 3-4 wk. Small cell & non small cell lung carcinoma: 80 mg/m2.
History of hypersensitivity to cisplatin or other platinum-containing compd. Preexisting renal or hearing impairment. Myelosuppressed & dehydrated patients Concurrent administration of yellow fever vaccine. Combination w/ phenytoin in prophylaxis. Lactation.
Special Precautions
Monitor renal, hepatic & haematopoiesis functions & serum electrolytes, audiometry prior to, during & after administration. Perform neurologic exam at regular intervals. Avoid Al-containing IV sets, needles, catheters & syringes. May influence ability to drive vehicles & use machinery. May cause irreversible infertility. Avoid pregnancy during & for min of 6 mth following treatment.
Adverse Reactions
Leukopenia, thrombocytopenia, anemia; anorexia, nausea, vomiting, diarrhea; hearing impairment; renal failure, nephrotoxicity, hyperuricemia; fever. Bone marrow failure; hyponatraemia. Sepsis; arrhythmia, bradycardia, tachycardia.
Drug Interactions
Potentiated nephrotoxic effect w/ cephalosporins, aminoglycosides, amphotericin B or contrast media. Potentially reduced renal elimination w/ cytostatic agents (eg, bleomycin & methotrexate). May increase renal toxicity of ifosfamide. Reduced blood lithium values w/ bleomycin & etoposide. May intensify nephrotoxicity w/ furosemide, hydralazine, diazoxide, & propranolol. Adjust dose of allopurinol, colchicine, probenecid or sulfinpyrazone as cisplatin increases serum uric acid conc. Increased protein excretion & hearing loss w/ ifosfamide. Potentiated ototoxic effect w/ aminoglycosides, loop diuretics. Yellow fever vaccine (contraindicated). Live vaccines (not recommended). Oral anticoagulants (regularly check INR). May mask ototoxicity symptoms w/ antihistamines, buclizine, cyclizine, loxapine, meclozine, phenothiazines, thioxanthenes or trimethobenzamides. May maintain serum conc of anticonvulsants at sub-therapeutic levels. May reduce absorption of phenytoin. May reduce clearance of paclitaxel. Increased myelosuppressive activity w/ myelosuppressives or radiation. Raynaud phenomenon may occur w/ bleomycin & vinblastine. Severe neurotoxic effects w/ docetaxel. Effectiveness may be diminished w/ chelating agents eg, penicillamine. Excessive immunosuppression w/ risk of lymphoproliferation w/ ciclosporin.
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01XA01 - cisplatin ; Belongs to the class of platinum-containing antineoplastic agents. Used in the treatment of cancer.
Cisplatin Ebewe infusion conc 0.5 mg/mL
100 mL x 1's;20 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in